Search
All Clinical Trials in United Kingdom
A listing of 3097 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
217 - 228 of 3097
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Recruiting
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1),... Read More
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), or with trastuzumab and capecitabine. Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow.
In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group.
During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The Oncology Institute of Hope and Innovation, Cerritos, California +79 locations
The Oncology Institute of Hope and Innovation, Cerritos, California
Valkyrie Clinical Trials, Los Angeles, California
University of California Irvine, Orange, California
Sharp Memorial Hospital, San Diego, California
Yale University School of Medicine, New Haven, Connecticut
Community Health Network, Indianapolis, Indiana
University of Iowa Hospitals and Clinics, Iowa City, Iowa
Massachusetts General Hospital, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts
Memorial Sloan-Kettering Cancer Center, New York, New York
Baptist Cancer Center - Memphis, Memphis, Tennessee
SCRI Oncology Partners, Nashville, Tennessee
Tennessee Oncology, Pllc, Nashville, Tennessee
The Methodist Hospital Research Institute, Houston, Texas
Virginia Cancer Specialists, PC, Fairfax, Virginia
Fred Hutchinson Cancer Research Center, Seattle, Washington
Brussels - UNIV Saint-Luc, Bruxelles, Not set
Edegem - UNIV UZ Antwerpen, Edegem, Not set
UZ Leuven, Leuven, Not set
UZ Antwerpen, Libramont-Chevigny, Not set
Centre Hospitalier Universitaire de Liège, Liege, Not set
CHU UCL Namur - Site De Sainte-Elisabeth, Namur, Not set
Jilin Province Cancer Hospital, Changchun, Not set
The First Hospital of Jilin University, Changchun, Not set
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Not set
Harbin Medical University Cancer Hospital, Harbin, Not set
Jiangsu Province Hospital, Nanjing, Not set
Fudan University Shanghai Cancer Center, Shanghai, Not set
Tianjin Cancer Hospital, Tianjin, Not set
Henan Cancer Hospital, Zhengzhou, Not set
INS Bergonie, Bordeaux cedex, Not set
CTR François Baclesse, Caen, Not set
CTR Georges-François Leclerc, Dijon, Not set
CTR Leon Berard, Lyon, Not set
INS Paoli-Calmettes, Marseille Cedex 9, Not set
HOP Tenon, Paris, Not set
CTR Eugène Marquis, Rennes cedex, Not set
Institut de Cancérologie de l'Ouest, Saint Herblain, Not set
Institut de Cancérologie de Strasbourg, Strasbourg, Not set
INS Claudius Regaud IUCT-Oncopole, Toulouse, Not set
Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Not set
Evang. Kliniken Essen-Mitte gGmbh, Essen, Not set
Asklepios Kliniken GmbH & Co. KGaA, Hamburg, Not set
Istituto Di Candiolo, Candiolo (TO), Not set
Az.Osp. Universitaria "Ospedali Riuniti", Foggia, Not set
Istituto Scientifico Romagnolo, Meldola (fc), Not set
IRCCS San Raffaele, Milano, Not set
Istituto Europeo di Oncologia, Milano, Not set
Humanitas Istituto Clinico Catanese S.p.A., Misterbianco (CT), Not set
Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli, Not set
Istituto Clinico Humanitas, Rozzano, Not set
Aichi Cancer Center Hospital, Aichi, Nagoya, Not set
Hakuaikai Sagara Hospital, Kagoshima-shi, Not set
Tokai University Hospital, Kanagawa, Isehara, Not set
Kanagawa Cancer Center, Kanagawa, Yokohama, Not set
National Cancer Center Hospital East, Kashiwa-shi, Not set
Kyoto University Hospital, Kyoto, Kyoto, Not set
Osaka International Cancer Institute, Osaka-shi, Not set
Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Not set
CHA Bundang Medical Center, Seongnam-si, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
Asan Medical Center, Seoul, Not set
Seoul National University Hospital, Seoul, Not set
Hospital Teresa Herrera, A Coruña, Not set
Hospital del Mar, Barcelona, Not set
Hospital Vall d'Hebron, Barcelona, Not set
Hospital Clínic de Barcelona, Barcelona, Not set
Hospital Duran i Reynals, L'Hospitalet de Llobregat, Not set
Hospital General Universitario Gregorio Marañón, Madrid, Not set
Clínica Universidad de Navarra - Madrid, Madrid, Not set
Fundación Jiménez Díaz, Madrid, Not set
Hospital Clínico San Carlos, Madrid, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital La Paz, Madrid, Not set
CIO Clara Campal, Madrid, Not set
Hospital Virgen Macarena, Sevilla, Not set
Instituto Valenciano de Oncología, Valencia, Not set
St James's University Hospital, Leeds, Not set
St Bartholomew's Hospital, London, Not set
Nottingham University Hospitals NHS Trust, Nottingham, Not set
Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Recruiting
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat.
Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs.
This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells.
This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body.
This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given to participants in combination with bevacizumab. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with bevacizumab and if it works to treat a certain solid tumor. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +26 locations
Mayo Clinic Hospital, Phoenix, Arizona
City of Hope, Duarte, California
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado
University of Colorado Hospital/University of Colorado, Aurora, Colorado
Florida Cancer Specialists, Orlando, Florida
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida
Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, Maryland
Beth Israel Deaconess Medical Center, Boston, Massachusetts
START Midwest, Grand Rapids, Michigan
Mayo Clinic Cancer Center, Rochester, Minnesota
Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee
SCRI Oncology Partners, Nashville, Tennessee
The University of Texas MD Anderson Cancer Center, Houston, Texas
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas
South Texas Accelerated Research Therapeutics Mountain Region, West Valley City, Utah
The Ottawa Hospital, Ottawa, Ontario
University Health Network, Princess Margaret Hospital, Toronto, Ontario
McGill University Health Centre, Montreal, Quebec
Institut Gustave Roussy, Villejuif Cedex, Paris
Gustave Roussy, Villejuif, Not set
Netherlands Cancer Institute, Amsterdam, Not set
Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), L'Hospitalet de Llobregat, Catalunya [cataluña]
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Not set
Karolinska University Hospital, Solna, Not set
ApoEx NKS, Stockholm, Not set
The University of Edinburgh, Edinburgh, Not set
Sarah Cannon Research Institute UK, London, Not set
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Recruiting
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Ironwood Cancer & Research Centers ( Site 0036), Chandler, Arizona +93 locations
Ironwood Cancer & Research Centers ( Site 0036), Chandler, Arizona
Yale New Haven Hospital ( Site 0001), New Haven, Connecticut
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007), Altamonte Springs, Florida
St. Luke's Cancer Institute: Boise ( Site 0037), Boise, Idaho
MedStar Franklin Square Medical Center ( Site 0031), Baltimore, Maryland
MedStar Good Samaritan Hospital ( Site 0079), Baltimore, Maryland
MedStar Montgomery Medical Center ( Site 0078), Olney, Maryland
Holy Cross Hospital ( Site 0091), Silver Spring, Maryland
Allina Health Cancer Institute ( Site 0069), Minneapolis, Minnesota
Comprehensive Cancer Centers of Nevada ( Site 0015), Las Vegas, Nevada
Renown Regional Medical Center ( Site 0005), Reno, Nevada
New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque, New Mexico
Instituto Alexander Fleming ( Site 2402), Mar De PLata, Buenos Aires
Instituto de Investigaciones Clinicas Mar del Plata ( Site 2401), Mar del Plata, Buenos Aires
Clinica Viedma ( Site 2403), Viedma, Rio Negro
Fundacion Estudios Clinicos ( Site 2405), Rosario, Santa Fe
Hospital Italiano de Cordoba ( Site 2406), Cordoba, Not set
AZ Maria Middelares ( Site 3103), Gent, Oost-Vlaanderen
ZAS Sint Augustinus ( Site 3102), Antwerpen, Vlaams Gewest
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 2301), São Jose do Rio Preto, Sao Paulo
Jewish General Hospital ( Site 0203), Montreal, Quebec
St. Marys Hospital Center ( Site 0201), Montreal, Quebec
Hopital Du Saint-Sacrement ( Site 0210), Québec, Quebec
Biocenter ( Site 2009), Concepcion, Biobio
IC La Serena Research ( Site 2007), La Serena, Coquimbo
FALP ( Site 2000), Santiago., Region M. De Santiago
Clínica UC San Carlos de Apoquindo ( Site 2008), Santiago, Region M. De Santiago
Bradfordhill ( Site 2001), Santiago, Region M. De Santiago
ONCOCENTRO APYS ( Site 2005), Vina del Mar, Valparaiso
The First Afflilated Hospital of Bengbu Medical College ( Site 5022), Bengbu, Anhui
The First Affiliated Hospital of Chongqing Medical University ( Site 5039), Chongqing, Chongqing
Chongqing University Three Gorges Hospital ( Site 5020), Chongqing, Chongqing
Sun Yat-Sen University Cancer Center ( Site 5014), Guangzhou, Guangdong
Guangxi Medical University Affiliated Tumor Hospital. ( Site 5008), Nanning, Guangxi
Jiangsu Province Hospital ( Site 5009), Nanjing, Jiangsu
Xuzhou Central Hospital ( Site 5036), Xuzhou, Jiangsu
The First Hospital of Jilin University ( Site 5003), Changchun, Jilin
Jinan Central Hospital ( Site 5031), Jinan, Shandong
LinYi Cancer Hospital ( Site 5021), Linyi, Shandong
Sichuan Cancer Hospital. ( Site 5018), Chengdu, Sichuan
Affiliated Tumor Hospital of Xinjiang Medical University ( Site 5006), Urumqi, Xinjiang
Zhejiang Cancer Hospital ( Site 5012), Hangzhou, Zhejiang
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 5024), Hangzhou, Zhejiang
Taizhou Hospital of Zhejiang Province ( Site 5029), Linhai, Zhejiang
Instituto de Cancerología ( Site 2206), Medellin., Antioquia
Centro Cancerologico del Caribe LTD ( Site 2209), Barranquilla, Atlantico
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 2203), Bogota., Distrito Capital De Bogota
Rambam Health Care Campus ( Site 3700), Haifa, Not set
Shaare Zedek Medical Center ( Site 3704), Jerusalem, Not set
Rabin Medical Center ( Site 3702), Petah Tikva, Not set
Sheba Medical Center ( Site 3701), Ramat Gan, Not set
Sourasky Medical Center ( Site 3703), Tel Aviv, Not set
Nagoya City University Hospital ( Site 5108), Nagoya, Aichi
Hokkaido University Hospital ( Site 5100), Sapporo, Hokkaido
Tokai University Hospital ( Site 5107), Isehara, Kanagawa
Mie University Hospital ( Site 5109), Tsu, Mie
The University of Osaka Hospital ( Site 5111), Suita, Osaka
Saitama Medical University International Medical Center ( Site 5116), Hidaka, Saitama
Showa Medical University Hospital ( Site 5103), Shinagawa, Tokyo
Fukushima Medical University Hospital ( Site 5101), Fukushima, Not set
Hiroshima City Hiroshima Citizens Hospital ( Site 5113), Hiroshima, Not set
Social medical corporation Hakuaikai Sagara Hospital ( Site 5114), Kagoshima, Not set
National Cancer Center ( Site 5202), Goyang-si, Kyonggi-do
Seoul National University Bundang Hospital ( Site 5204), Seongnam, Kyonggi-do
Kyungpook National University Chilgok Hospital ( Site 5205), Daegu, Kyongsangbuk-do
Seoul National University Hospital ( Site 5200), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 5201), Seoul, Not set
Samsung Medical Center ( Site 5203), Seoul, Not set
Harbour Cancer & Wellness ( Site 5600), Newmarket, Auckland
Pratia MCM Krakow ( Site 3812), Krakow, Malopolskie
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3801), Siedlce, Mazowieckie
Mazowiecki Szpital Onkologiczny ( Site 3807), Wieliszew, Mazowieckie
Szpitale Pomorskie Sp. z o. o. ( Site 3805), Gdynia, Pomorskie
Szpital Wojewodzki im. Mikolaja Kopernika w Koszalinie ( Site 3800), Koszalin, Zachodniopomorskie
Institutul Oncologic Cluj ( Site 4701), Cluj Napoca, Cluj
S.C. Radiotherapy Center Cluj S.R.L ( Site 4705), Comuna Floresti, Cluj
Centrul de Oncologie "Sfântul Nectarie" ( Site 4702), Craiova, Dolj
Centrul Medical Neolife- Baneasa ( Site 4706), Bucuresti, Not set
Hospital Clinico San Carlos ( Site 4100), Madrid, Madrid, Comunidad De
Hospital General Universitario de Valencia ( Site 4102), Valencia, Valenciana, Comunitat
Parc de Salut Mar - Hospital del Mar ( Site 4106), Barcelona, Not set
Hospital Beata María Ana ( Site 4105), Madrid, Not set
Hospital Universitario Ramon y Cajal ( Site 4103), Madrid, Not set
Taichung Veterans General Hospital ( Site 5303), Taichung, Not set
National Cheng Kung University Hospital ( Site 5304), Tainan, Not set
National Taiwan University Hospital ( Site 5300), Taipei, Not set
Mackay Memorial Hospital ( Site 5301), Taipei, Not set
Chang Gung Memorial Hospital ( Site 5302), Taoyuan, Not set
Faculty of Medicine Siriraj Hospital ( Site 5800), Bangkok, Krung Thep Maha Nakhon
Songklanagarind hospital ( Site 5801), HatYai, Songkhla
Faculty of Medicine - Khon Kaen University ( Site 5802), Khon Kaen, Not set
Royal Cornwall Hospital ( Site 4003), Truro, Cornwall
St Bartholomew's Hospital ( Site 4001), London, London, City Of
Nottingham University Hospital NHS Trust ( Site 4009), Nottingham, Nottinghamshire
Conditions: Triple Negative Breast Neoplasms
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Recruiting
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate.
* Cohort A: Participants with relapsed or refractory MCL r... Read More
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate.
* Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell therapy or ineligible for CAR-T cell therapy
* Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior systemic therapy
* Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi
* Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory disease after at least 2 prior systemic therapies and have no other available therapy
* Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic therapies and have no other available therapy
The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded independent central review (BICR).
As of Amendment 07, Cohort D is closed to enrollment of participants with CLL and enrollment of participants into Arm 2 (zilovertamab vedotin at Dose 2 on Days 1 \& 8 of each 3 Week Cycle (Q2/3W)). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +108 locations
Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska
Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona
Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona
University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008), Aurora, Colorado
Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois
University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038), Fairway, Kansas
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky
Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland
Tufts Medical Center ( Site 0024), Boston, Massachusetts
Massachusetts General Hospital ( Site 0018), Boston, Massachusetts
Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts
University of Michigan ( Site 0009), Ann Arbor, Michigan
Henry Ford Hospital ( Site 0035), Detroit, Michigan
Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0004), Columbus, Ohio
Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota
Medical Oncology Associates, PS ( Site 0005), Spokane, Washington
University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin
MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte
Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1809), Rio de Janeiro, Not set
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), Sao Paulo, Not set
Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set
BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia
The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick
QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia
Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0203), London, Ontario
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario
Jewish General Hospital ( Site 0202), Montreal, Quebec
Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan
IC La Serena Research ( Site 1909), La Serena., Coquimbo
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago., Region M. De Santiago
Clínica Inmunocel ( Site 1910), Santiago, Region M. De Santiago
Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago
Beijing Cancer hospital ( Site 1200), Beijing, Beijing
Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong
Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong
Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong
Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei
Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei
The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu
The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu
The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi
Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi
Jilin Province Tumor Hospital-oncology department ( Site 1220), Chuangchun, Jilin
Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai
West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan
The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang
Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang
Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto
Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj
Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set
North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa
Universitaetsklinikum Ulm. ( Site 0502), Ulm, Baden-Wurttemberg
Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen
St. James's Hospital ( Site 0600), Dublin, Not set
Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set
Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set
Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set
Carmel Hospital ( Site 0709), Haifa, Not set
Hadassah Medical Center ( Site 0701), Jerusalem, Not set
Galilee Medical Center ( Site 0710), Nahariya, Not set
Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set
IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron ( Site 0800), Bologna, Emilia-Romagna
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant ( Site 0803), Alessandria, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Not set
National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi
Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido
Tokai University Hospital ( Site 1100), Isehara, Kanagawa
Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi
Kindai University Hospital ( Site 1102), Sayama, Osaka
National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo
Cancer Institute Hospital of JFCR ( Site 1101), Koto, Tokyo
Kyushu University Hospital ( Site 1105), Fukuoka, Not set
Okayama University Hospital ( Site 1107), Okayama, Not set
Seoul National University Hospital ( Site 1300), Seoul, Not set
Samsung Medical Center ( Site 1301), Seoul, Not set
Centro Medico Monte Carmelo ( Site 1702), Arequipa, Ariqipa
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie
Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie
Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1002), Warszawa, Mazowieckie
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 1010), Kielce, Swietokrzyskie
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1007), Olsztyn, Warminsko-mazurskie
Champalimaud Foundation ( Site 2002), Lisbon, Lisboa
Unidade Local de Saude de Braga - Hospital de Braga ( Site 2001), Braga, Not set
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set
National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona
Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Cataluna
MD Anderson Cancer Center ( Site 4006), Madrid, Madrid, Comunidad De
Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( Site 4001), Salamanca, Not set
Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan
Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan
Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set
Trakya University ( Site 6005), Edirne, Not set
Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set
Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set
The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall
University College London Hospital ( Site 7001), London, London, City Of
The Churchill Hospital ( Site 7002), Oxford, Oxfordshire
The Christie NHS Foundation Trust ( Site 7007), Manchester, Not set
Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Recruiting
In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens with FA who are younger than 16 years old. The main objective of this study is to learn how BIIB141 works in the body and about its safety in children and teens who are 2 to 15... Read More
In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens with FA who are younger than 16 years old. The main objective of this study is to learn how BIIB141 works in the body and about its safety in children and teens who are 2 to 15 years old.
The main questions researchers want to answer in this study are:
* How does BIIB141 affect the participants' FA symptoms balance and stability?
* How many participants have medical problems during the study?
* Are there any changes in the participants' overall health during the study?
* Are there any changes in the participants' heart health?
* Are there any changes in how the participants move through puberty? Puberty is the time in someone's life when their body changes from a child to an adult.
Researchers will also learn more about:
- How the body processes BIIB141 in children and teens
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center.
* There are 2 parts in this study. During Part 1, participants will take either BIIB141 or a placebo once a day.
* In Part 1, participants will take BIIB141 or the placebo in a study research center on Day 1, and then at in-person visits at Week 4, Week 12, Week 26, and Week 52. On all other days, they will take BIIB141 or the placebo at home. Part 1 lasts up to 52 weeks.
* During Part 2, participants from Part 1 will either continue taking BIIB141 or start it if they were taking the placebo. Part 2 will last up to 104 weeks.
* In Part 1, participants will have up to 10 visits to their study research center and a phone call at Week 2. In Part 2, participants will have visits at Weeks 4, 8,12, 26, and every 26 weeks after that until they leave the study, and a phone call at Week 2. There will be a final phone call to check on the participants' health 31 days after their last dose.
* Each participant will be in the study for up to about 3 years Read Less
Gender:
ALL
Ages:
Between 2 years and 15 years
Trial Updated:
08/14/2025
Locations: UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California +26 locations
UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California
Norman Fixel Institute for Neurological Diseases UF Health, Gainesville, Florida
USF Health Morsani College of Medicine Department of Neurology, Tampa, Florida
Children's Hospital of Philadelphia Buerger Center, Philadelphia, Pennsylvania
St Jude Children's Research Hospital, Memphis, Tennessee
Children's Hospital of the King's Daughters, Norfolk, Virginia
Murdoch Childrens Research Institute (MCRI), Parkville, Victoria
Universitätsklinikum Innsbruck, Innsbruck, Not set
L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME, Brasília, Distrito Federal
University of Campinas (UNICAMP) School of Medical Sciences, Campinas, Sao Paulo
PSEG Centro de Pesquisa Clinica, Sao Paulo, Not set
McGill University, Montreal, Quebec
Rigshospitalet - Juliane Marie Centret (JMC) Copenhagen, Copenhagen, Not set
CHU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, Hérault
AP-HP - Hôpital Armand Trousseau, Paris, Not set
Universitätsklinikum Aachen, Aachen, Not set
UKGM - Universitätsklinikum Giessen und Marburg GmbH - Standort Gießen, Giessen, Not set
UKE Hamburg, Hamburg, Not set
CHI at Temple Street, Dublin, Not set
Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio
IRCCS Eugenio Medea - Polo. Scientifico Veneto, Conegliano, Veneto
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Not set
Radboud Universitair Medisch Centrum, Nijmegen, Not set
Hospital Sant Joan de Deu, Espluges De Llobregat, Not set
Hospital Universitario La Paz - PPDS, Madrid, Not set
Sheffield Children's Hospital, Sheffield, South Yorkshire
University College London, Institue of Neurology, London, Not set
Conditions: Friedreich Ataxia
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF). Read Less
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
08/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +115 locations
University of Alabama at Birmingham, Birmingham, Alabama
Colorado Heart and Vascular - Lakewood, Lakewood, Colorado
Ascension St. Vincent's Riverside Hospital, Jacksonville, Florida
Local Institution - 0003, Miami, Florida
Local Institution - 0099, Miami, Florida
Local Institution - 0014, Atlanta, Georgia
Local Institution - 0048, Atlanta, Georgia
Bluhm Cardiovascular Institute of Northwestern, Chicago, Illinois
Chicago Medical Research, LLC, Hazel Crest, Illinois
Ascension Medical Group St. Vincent - Indianapolis Heart Care, Indianapolis, Indiana
Local Institution - 0045, Indianapolis, Indiana
St. Louis Heart and Vascular, Saint Louis, Missouri
Local Institution - 0043, Saint Louis, Missouri
Capital Cardiology Associates, Albany, New York
Local Institution - 0105, Brooklyn, New York
Weill Cornell Medicine, New York, New York
Local Institution - 0059, Rochester, New York
Local Institution - 0076, Rochester, New York
Local Institution - 0094, Rosedale, New York
Local Institution - 0095, Durham, North Carolina
Local Institution - 0058, Cincinnati, Ohio
Local Institution - 0041, Oklahoma City, Oklahoma
South Oklahoma Heart Research, Oklahoma City, Oklahoma
Local Institution - 0078, Abington, Pennsylvania
Tennessee Center for Clinical Trials, Tullahoma, Tennessee
Local Institution - 0104, Austin, Texas
University of Texas Southwestern Medical Center, Dallas, Texas
Angiocardiac Care of Texas - PA - PPDS, Houston, Texas
Local Institution - 0051, Houston, Texas
Local Institution - 0066, Falls Church, Virginia
Local Institution - 0054, General San Martín, Buenos Aires
Local Institution - 0107, Zárate, Buenos Aires
Local Institution - 0115, Zárate, Buenos Aires
Local Institution - 0090, Córdoba, Cordoba
Local Institution - 0053, Córdoba, Cordoba
Local Institution - 0073, Rosario, Santa FE
Local Institution - 0061, San Miguel De Tucumán, Tucuman
Local Institution - 0060, Ciudad Autonoma de Buenos Aires, Not set
Local Institution - 0067, Ciudad Autonoma de Buenos Aires, Not set
Local Institution - 0068, Ciudad Autónoma de Buenos Aires, Not set
Local Institution - 0074, Córdoba, Not set
Local Institution - 0069, Salta, Not set
Local Institution - 0102, Santa Fe, Not set
Hamilton General Hospital, Hamilton, Ontario
Medicus MFC Inc., Toronto, Ontario
Local Institution - 0030, Toronto, Ontario
Local Institution - 0040, Toronto, Ontario
Local Institution - 0011, Montreal, Quebec
Local Institution - 0035, Trois-Rivieres, Quebec
Peking Union Medical College Hospital - East Campus, Beijing, Beijing
Local Institution - 0087, Guangzhou, Guangdong
Local Institution - 0080, Luoyang, Henan
Local Institution - 0079, Changsha, Hunan
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang
Local Institution - 0109, Jerusalem, Yerushalayim
Local Institution - 0113, Jerusalem, Yerushalayim
Local Institution - 0112, Be'er - Ya'akov, Not set
Local Institution - 0111, Be'er Sheva, Not set
Local Institution - 0108, Haifa, Not set
Local Institution - 0110, Petah Tikva, Not set
Local Institution - 0106, Rehovot, Not set
Local Institution - 0116, Safed, Not set
Local Institution - 0019, Napoli, Campania
Local Institution - 0023, Milano, Lombardia
Local Institution - 0033, Milano, Lombardia
IRCCS Policlinico San Donato, San Donato Milanese, Lombardia
Local Institution - 0050, San Donato Milanese, Lombardia
Local Institution - 0027, Foggia, Puglia
Local Institution - 0038, Foggia, Puglia
Local Institution - 0052, Massa, Toscana
Local Institution - 0009, Bergamo, Not set
Local Institution - 0017, Pisa, Not set
Hyogo Prefectural Harima-Himeji General Medical Center, Himeji-Shi, Hyogo
National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa
Okayama Rosai Hospital, Okayama-Shi, Okayama
Kishiwada Tokushukai Hospital, Kishiwada, Osaka
Takatsuki Red Cross Hospital, Takatsuki-Shi, Osaka
Local Institution - 0088, Daegu, Daegu Gwang'yeogsi
Local Institution - 0084, Daejeon, Daejeon Gwang'yeogsi
Local Institution - 0083, Gwangju, Gwangju Gwang'yeogsi
Inha University Hospital, Jung-gu, Incheon Gwang'yeogsi
Local Institution - 0085, Seoul, Seoul Teugbyeolsi
Local Institution - 0114, Seoul, Seoul Teugbyeolsi
Local Institution - 0055, Seoul, Seoul Teugbyeolsi
Local Institution - 0086, Busan, Not set
Local Institution - 0098, Seongnam-si, Not set
Local Institution - 0081, Seoul, Not set
Clinical Trials UMED Sp. z o.o., Lódz, Lódzkie
Local Institution - 0031, Bialystok, Podlaskie
Local Institution - 0044, Bialystok, Podlaskie
Local Institution - 0020, Lublin, Woj. Lubelskie
Local Institution - 0049, Lublin, Woj. Lubelskie
Local Institution - 0006, Krakow, Not set
Local Institution - 0024, Oswiecim, Not set
Local Institution - 0012, Hospitalet de Llobregat, Barcelona
Local Institution - 0025, Majadahonda, Madrid
Local Institution - 0047, Majadahonda, Madrid
Hospital Universitario Virgen de La Arrixaca, El Palmar, Murcia
Local Institution - 0039, El Palmar, Murcia
Local Institution - 0042, Malaga, Málaga
Local Institution - 0026, Madrid, Not set
Local Institution - 0034, Madrid, Not set
Local Institution - 0032, Malaga, Not set
Hospital Nuestra Señora de Valme, Sevilla, Not set
Local Institution - 0046, Sevilla, Not set
Local Institution - 0010, Valencia, Not set
Local Institution - 0063, Harrow, Greater London
Local Institution - 0071, North Shields, Northumberland
Local Institution - 0062, Oxford, Oxfordshire
Local Institution - 0072, Leeds, Yorkshire
Local Institution - 0057, Sheffield, Yorkshire
Local Institution - 0101, Bristol, Not set
Local Institution - 0097, Dundee, Not set
Local Institution - 0075, London, Not set
Local Institution - 0065, Stockton-On-Tees, Not set
Local Institution - 0064, Wolverhampton, Not set
Conditions: Heart Failure
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Recruiting
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Arkansas Urology, Little Rock, Arkansas +192 locations
Arkansas Urology, Little Rock, Arkansas
Genesis Research LLC, Los Alamitos, California
USC Norris Comprehensive Cancer Center, Los Angeles, California
University of California Irvine Medical Center, Orange, California
Genesis Research, San Diego, California
Genesis Research LLC, Sherman Oaks, California
University of Colorado Cancer Center Anschultz Cancer Pavilion, Aurora, Colorado
Colorado Clinical Research, Lakewood, Colorado
Moffitt Cancer Center, Tampa, Florida
Northwestern University, Chicago, Illinois
First Urology, Jeffersonville, Indiana
Wichita Urology Group, Wichita, Kansas
Ochsner Health System, New Orleans, Louisiana
Chesapeake Urology Research Associates, Hanover, Maryland
Brigham And Women's Hospital, Boston, Massachusetts
Karmanos Cancer Institute, Detroit, Michigan
Comprehensive Urology, Royal Oak, Michigan
Mercy Research, Saint Louis, Missouri
Specialty Clinical Research of St Louis, Saint Louis, Missouri
The Urology Center, PC, Omaha, Nebraska
Cancer Institute Of New Jersey, New Brunswick, New Jersey
Integrated Medical Professionals, New York, New York
Memorial Sloan Kettering Cancer Center, New York, New York
Associated Medical Professionals of Ny, Syracuse, New York
SUNY Upstate Med Univ, Syracuse, New York
Levine Cancer Institute, Charlotte, North Carolina
Associated Urologists of North Carolina, Raleigh, North Carolina
MidLantic Urology, Bala-Cynwyd, Pennsylvania
Keystone Urology Specialists, Lancaster, Pennsylvania
Carolina Urologic Research Center, Myrtle Beach, South Carolina
The Conrad Pearson Clinic, Germantown, Tennessee
University of Tennessee Medical Center, Knoxville, Tennessee
Urology Associates, Nashville, Tennessee
Urology Austin, Austin, Texas
Urology Clinics of North Texas, Dallas, Texas
UT Southwestern, Dallas, Texas
Houston Metro Urology, Houston, Texas
Spokane Urology, Spokane, Washington
Investigaciones Clinico Moleculares (ICM), Caba, Not set
Hospital Sirio Libanes, Ciudad Autonoma de Buenos Aires, Not set
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, Not set
Centro Urologico Profesor Bengio, Cordoba, Not set
Hospital Privado de la Comunidad, Mar del Plata, Not set
Sanatorio de la Mujer, Rosario, Not set
Medizinische Universitaet Graz, Graz, Not set
Medizinische Universitat Innsbruck, Innsbruck, Not set
Ordensklinikum Linz GmbH Elisabethinen, Linz, Not set
Universitaetsklinikum Salzburg Landeskrankenhaus, Salzburg, Not set
Medical University Vienna MUV, Wien, Not set
Onze -Lieve-Vrouwziekenhuis, Aalst, Not set
AZ Sint-Jan, Brugge, Not set
UZ Antwerpen, Edegem, Not set
AZ Maria Middelares, Gent, Not set
Universitair Ziekenhuis Gasthuisberg, Leuven, Not set
Vitaz, Sint Niklaas, Not set
CHU UCL Namur - Site Godinne, Yvoir, Not set
Fundacao Pio XII, Barretos, Not set
Universidade Estadual De Campinas, Campinas, Not set
Liga Norte Riograndense Contra O Cancer, Natal, Not set
Associacao Hospitalar Moinhos de Vento, Porto Alegre, Not set
Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Not set
HBA SA Assitencia Medica e Hospitalar, Salvador, Not set
Fundacao do ABC Centro Universitario FMABC, Santo Andre, Not set
Irmandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo, Not set
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Not set
Real e Benemérita Associação Portuguesa de Beneficência, Sao Paulo, Not set
Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Not set
Beijing Friendship Hospital Capital Medical University, Beijing, Not set
Peking University Third Hospital, Beijing, Not set
Hunan Cancer hospital, Changsha, Not set
The Third People's Hospital of Chengdu, Cheng Du Shi, Not set
West China School of Medicine/West China Hospital, Sichuan University, Cheng Du Shi, Not set
Chongqing Cancer Hospital, Chong Qing, Not set
Fujian Medical University Union Hospital, Fu Zhou Shi, Not set
Sun Yat Sen University Cancer Center, Guang Zhou Shi, Not set
Nanjing Drum Tower Hospital, Nan Jing Shi, Not set
Zhongda Hospital Southeast University, Nan Jing Shi, Not set
Huadong Hospital Affiliated to Fudan University, Shanghai, Not set
The Second Hospital Of Tianjin Medical University, Tianjin, Not set
Cancer Hospital of Xinjiang Medical University, Urumqi, Not set
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set
Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology, Wu Han Shi, Not set
The First Affiliated Hospital of Xian Jiaotong University, XI An Shi, Not set
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Not set
Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set
Fakultni nemocnice Olomouc, Olomouc, Not set
Vseobecna fakultni nemocnice v Praze, Praha 2, Not set
Fakultni Thomayerova nemocnice, Praha 4, Not set
Fakultni nemocnice v Motole, Praha, Not set
Aarhus University Hospital, Aarhus, Not set
Herlev Hospital, Herlev, Not set
Rigshospitalet, Kobenhavn, Not set
Odense Universitetshospital, Odense, Not set
Zealand University Hospital, Roskilde, Not set
Hospital Center University De Lille, Lille, Not set
Polyclinique de Limoges - Francois Chenieux, Limoges, Not set
Hôpital Edouard Herriot, Lyon, Not set
Institut Paoli Calmettes, Marseille, Not set
Hopital Saint Louis, Paris, Not set
CHU Pitie Salpetriere, Paris, Not set
APHP - Hopital Bichat - Claude Bernard, Paris, Not set
Clinique de la Croix du Sud, Quint-Fonsegrives, Not set
Chu Rennes Hopital Pontchaillou, Rennes, Not set
CHU Rangueil, Toulouse, Not set
Institut Gustave Roussy, Villejuif, Not set
Charite - Universitaetsmedizin Berlin (CCM), Berlin, Not set
Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie, Braunschweig, Not set
Urologische Gemeinschaftspraxis, Dresden, Not set
Universitaetsklinikum Frankfurt, Frankfurt am Main, Not set
Urologikum Hamburg MVZ - Germany, Hamburg, Not set
Marien hospital Herne, Herne, Not set
Universitatsklinikum Jena, Jena, Not set
Studienzentrum Bayenthal, Koeln, Not set
Klinikum rechts der Isar an der Technischen Universitat Munchen, Munchen, Not set
Klinikum St. Elisabeth Straubing GmbH, Straubing, Not set
Katharinenhospital Innere Medizin, Stuttgart, Not set
Prince Of Wales Hospital, Hong Kong, Not set
Queen Mary Hospital, Hong Kong, Not set
Cork University Hospital, Cork, Not set
Mater Misericordiae University Hospital, Dublin, Not set
Mater Private Hospital, Dublin, Not set
Adelaide and Meath Hospital, Dublin, Not set
Rambam Health Care Campus, Haifa, Not set
Hadassah University Hospita Ein Kerem, Jerusalem, Not set
Sheba Medical Center, Ramat Gan, Not set
Ziv Medical Center, Safed, Not set
Sourasky Medical Center, Tel-Aviv, Not set
Ospedale S. Donato Arezzo, USL 8 - U.O. Oncologia Medica, Arezzo, Not set
Cliniche Humanitas Gavazzeni, Bergamo, Not set
ASST Spedali Civili Brescia, Brescia, Not set
Ospedale San Raffaele, Milano, Not set
Istituto Dei Tumori Di Milano, Milano, Not set
Universita Campus Bio-Medico di Roma, Roma, Not set
Istituto Nazionale Tumori Regina Elena, Roma, Not set
Istituto Clinico Humanitas, Rozzano, Not set
A.O.Citta della Salute e della Scienza di Torino, Torino, Not set
Hyogo Prefectural Amagasaki General Medical Center, Amagasaki shi, Not set
St Marianna University Hospital, Kawasaki Shi, Not set
Kobe City Medical Center General Hospital, Kobe City, Not set
National Hospital Organization Kumamoto Medical Center, Kumamoto City, Not set
Osaka International Cancer Institute, Osaka, Not set
Gunma Prefectural Cancer Center, Ota, Not set
Saitama Medical Center, Saitama, Not set
JRC Wakayama Medical Center, Wakayama, Not set
Yokohama Municipal Citizen's Hospital, Yokohama, Not set
Yokohama City University Medical Center, Yokohama, Not set
Yokosuka Kyosai Hospital, Yokosuka, Not set
Chungbuk National University Hospital, Chungcheongbuk Do, Not set
National Cancer Center, Gyeonggi-do, Not set
Chonnam National University Hwasun Hospital, Jeollanam-do, Not set
Samsung Medical Center, Seoul, Not set
The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set
Seoul National University Hospital, Seoul, Not set
Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Not set
IN VIVO Sp. z o.o, Bydgoszcz, Not set
Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy, Bydgoszcz, Not set
Uniwersytecki Szpital Kliniczny nr 4, Lublin, Not set
Wojewodzki Szpital im Sw Ojca Pio w Przemyslu, Przemysl, Not set
Szpital Wojewodzki Im Sw Lukasza Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Tarnowie, Tarnow, Not set
Medicover Integrated Clinical Services Sp z o o, Torun, Not set
Mazowiecki Szpital Onkologiczny Sp z o o, Wieliszew, Not set
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu, Wroclaw, Not set
Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii, Wroclaw, Not set
Hosp Univ A Coruna, A Coruna, Not set
Hosp. Univ. de La Ribera, Alzira, Not set
Fund. Puigvert, Barcelona, Not set
Hosp Univ Vall D Hebron, Barcelona, Not set
Hosp Clinic de Barcelona, Barcelona, Not set
Hosp. Puerta Del Mar, Cadiz, Not set
Hosp. Gral. Univ. de Castellon, Castellon, Not set
Hosp. de Jerez de La Frontera, Jerez De La Frontera, Not set
Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set
Clinica Univ. de Navarra, Madrid, Not set
Hosp. Univ. 12 de Octubre, Madrid, Not set
Hosp Virgen de La Victoria, Malaga, Not set
Hosp. Univ. Central de Asturias, Oviedo, Not set
Hosp.Univ.Parc Tauli, Sabadell, Not set
Hosp. Virgen Del Rocio, Sevilla, Not set
Hosp. Clinico Univ. de Valencia, Valencia, Not set
Adana Baskent Practice and Research Hospital, Adana, Not set
Ankara University Medical Faculty, Ankara, Not set
Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Not set
Istanbul University Cerrahpasa Medical Faculty, Istanbul, Not set
T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi, Istanbul, Not set
Kartal Dr Lutfi Kirdar sehir Hastanesi, Istanbul, Not set
Dokuz Eylul University Medical Faculty, Izmir, Not set
Southmead Hospital, Bristol, Not set
St Bartholomews Hospital, London, Not set
Charing Cross Hospital, London, Not set
Newcastle Freeman Hospital, Newcastle Upon Tyne, Not set
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Not set
Southampton General Hospital, Southampton, Not set
Royal Marsden Hospital, Sutton, Not set
Conditions: Non-Muscle Invasive Bladder Cancer
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).
The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied.
Study details include:
The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension.
The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension.
The double-blind placebo-controlled treatment duration will be up to 28 weeks. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: FOMAT Medical Research - inSite Digestive Health Care - Arcadia- Site Number : 8400052, Arcadia, California +110 locations
FOMAT Medical Research - inSite Digestive Health Care - Arcadia- Site Number : 8400052, Arcadia, California
Ventura County Gastroenterology Medical Group- Site Number : 8400010, Camarillo, California
Om Research - Lancaster - 15th Street West- Site Number : 8400001, Lancaster, California
United Gastroenterologists - Los Alamitos- Site Number : 8400014, Los Alamitos, California
Advanced Research Institute - Denver- Site Number : 8400048, Denver, Colorado
Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400040, Miami Lakes, Florida
GI Pros- Site Number : 8400034, Naples, Florida
GCP Clinical Research- Site Number : 8400007, Tampa, Florida
Archbold Memorial Hospital- Site Number : 8400044, Thomasville, Georgia
Hutchinson Clinic- Site Number : 8400020, Hutchinson, Kansas
Boston Specialists- Site Number : 8400051, Boston, Massachusetts
Berkshire Medical Center, Inc.- Site Number : 8400017, Pittsfield, Massachusetts
Gastroenterology Associates of Western Michigan, P.L.C.- Site Number : 8400004, Wyoming, Michigan
Mayo Clinic Hospital Rochester- Site Number : 8400049, Rochester, Minnesota
Washington University- Site Number : 8400025, Saint Louis, Missouri
Advanced Research Institute- Site Number : 8400036, Reno, Nevada
Sanmora Bespoke Clinical Research Solutions- Site Number : 8400015, East Orange, New Jersey
Allied Health Clinical Research Organization, LLC- Site Number : 8400053, Freehold, New Jersey
Ospedale Maggiore Policlinico Milano-Site Number : 3800002, Charlotte, North Carolina
M3-Emerging Medical Research- Site Number : 8400008, Raleigh, North Carolina
Velocity Clinical Research - Providence- Site Number : 8400002, East Greenwich, Rhode Island
ClinSearch - Chattanooga - Shallowford Road- Site Number : 8400012, Chattanooga, Tennessee
Quality Medical Research- Site Number : 8400018, Nashville, Tennessee
Advanced Research Institute- Site Number : 8400030, Cedar Park, Texas
MedCare Pharma - Houston - Cypress Creek Parkway- Site Number : 8400016, Houston, Texas
LinQ Research, LLC- Site Number : 8400028, Pearland, Texas
DM Clinical Research - Tomball- Site Number : 8400042, Tomball, Texas
Advanced Research Institute - Sandy- Site Number : 8400046, Sandy, Utah
Velocity Clinical Research - Salt Lake City- Site Number : 8400023, West Jordan, Utah
Clinical Research Partners - Richmond - Forest Avenue- Site Number : 8400011, Richmond, Virginia
GI Alliance- Site Number : 8400033, Tacoma, Washington
Investigational Site Number : 0320010, Quilmes, Buenos Aires
Investigational Site Number : 0320008, San Isidro, Buenos Aires
Investigational Site Number : 0320005, Rosario, Santa Fe
Investigational Site Number : 0320002, San Miguel de Tucumán, Tucumán
Investigational Site Number : 0320007, Buenos Aires, Not set
Investigational Site Number : 0320001, Buenos Aires, Not set
Investigational Site Number : 0320003, Córdoba, Not set
Investigational Site Number : 0360002, Sydney, New South Wales
Investigational Site Number : 0360001, Mackay, Queensland
Investigational Site Number : 0320012, Maroochydore, Queensland
Investigational Site Number : 0360005, Melbourne, Victoria
Investigational Site Number : 0560002, Brussels, Not set
Investigational Site Number : 0560001, Leuven, Not set
Hospital Sao Rafael- Site Number : 0760005, Salvador, Bahia
Centro de Pesquisas da Clínica IBIS- Site Number : 0760006, Salvador, Bahia
Chronos Pesquisa Clínica- Site Number : 0760002, Brasília, Distrito Federal
Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 8400013, Vitoria, Espírito Santo
Hospital Moinhos de Vento- Site Number : 0760004, Porto Alegre, Rio Grande Do Sul
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001, Porto Alegre, Rio Grande Do Sul
Praxis Pesquisa Medica- Site Number : 0760008, Santo Andre, São Paulo
Investigational Site Number : 1240001, Vancouver, British Columbia
Investigational Site Number : 1240002, Victoria, British Columbia
Investigational Site Number : 1520006, Concepción, Biobío
Investigational Site Number : 1520005, Talcahuano, Biobío
Investigational Site Number : 1520007, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520004, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520001, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 2030002, Brno, Not set
Investigational Site Number : 2030006, Havířov, Not set
Investigational Site Number : 2030005, Klatovy, Not set
Investigational Site Number : 2030001, Prague, Not set
Investigational Site Number : 2030003, Prague, Not set
Investigational Site Number : 0320009, Kuopio, Buenos Aires
Investigational Site Number : 2460002, Helsinki, Not set
Investigational Site Number : 2460003, Tampere, Not set
Investigational Site Number : 2460001, Turku, Not set
Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin Tripode- Site Number : 8400006, Bordeaux, Idaho
Investigational Site Number : 2500002, Nice, Not set
Investigational Site Number : 2500001, Paris, Not set
Investigational Site Number : 2760004, Berlin, Not set
Investigational Site Number : 2760001, Halle, Not set
Investigational Site Number : 2760002, Mainz, Not set
Investigational Site Number : 3000001, Athens, Not set
Investigational Site Number : 3000002, Athens, Not set
Investigational Site Number : 3760002, Afula, Not set
Investigational Site Number : 3760006, Be'er Sheva, Not set
Investigational Site Number : 3760004, Jerusalem, Not set
Investigational Site Number : 3760003, Petah Tikva, Not set
Investigational Site Number : 3760007, Ramat Hasharon, Not set
Investigational Site Number : 3760001, Rehovot, Not set
Azienda Ospedaliera di Padova-Site Number : 3800004, Padova, Veneto
Ospedale di Cisanello-Site Number : 3800003, Pisa, Not set
Investigational Site Number : 5280001, Amsterdam, Not set
Investigational Site Number : 5280002, Arnhem, Not set
Investigational Site Number : 6160005, Wroclaw, Dolnoslaskie
Investigational Site Number : 6160001, Krakow, Malopolskie
Investigational Site Number : 6160002, Warsaw, Mazowieckie
Investigational Site Number : 6160004, Poznan, Wielkopolskie
Investigational Site Number : 7030001, Košice, Not set
Investigational Site Number : 7030003, Nitra, Not set
Investigational Site Number : 7030004, Šahy, Not set
Investigational Site Number : 7240006, Barcelona, Barcelona [Barcelona]
Investigational Site Number : 7240009, Chiclana de La Frontera, Cádiz
Investigational Site Number : 7240002, Seville, Sevilla
Investigational Site Number : 7240007, Madrid, Not set
Investigational Site Number : 7240003, Madrid, Not set
Investigational Site Number : 7240004, Málaga, Not set
Investigational Site Number : 7240008, Sevilla, Not set
Investigational Site Number : 7522001, Linköping, Not set
Investigational Site Number : 7521001, Mölndal, Not set
Investigational Site Number : 7520003, Stockholm, Not set
Investigational Site Number : 7520001, Uppsala, Not set
Investigational Site Number : 7920004, Antalya, Not set
Investigational Site Number : 7920003, Gaziantep, Not set
Investigational Site Number : 7920006, Istanbul, Not set
Investigational Site Number : 7920001, Mersin, Not set
Investigational Site Number : 7920005, Sanliurfa, Not set
Investigational Site Number : 7920002, Zonguldak, Not set
Investigational Site Number : 8260001, Oxford, Oxfordshire
Investigational Site Number : 8260002, Sheffield, Not set
Conditions: Coeliac Disease, Celiac Disease
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Los Angeles Cancer Network ( Site 0025), Glendale, California +125 locations
Los Angeles Cancer Network ( Site 0025), Glendale, California
Stanford Cancer Center ( Site 0024), Palo Alto, California
Exempla Lutheran Medical Center ( Site 0014), Golden, Colorado
Parkview Research Center at Parkview Regional Medical Center ( Site 0006), Fort Wayne, Indiana
University of Michigan ( Site 0003), Ann Arbor, Michigan
Duke University Health System (DUHS) ( Site 0012), Durham, North Carolina
Oregon Health & Science University ( Site 0018), Portland, Oregon
University of Texas MD Anderson Cancer Center ( Site 0026), Houston, Texas
University of Texas Health Science Center at San Antonio ( Site 0021), San Antonio, Texas
University of Virginia ( Site 0020), Charlottesville, Virginia
VCU Health Adult Outpatient Pavillion ( Site 0008), Richmond, Virginia
Hospital Universitario Austral ( Site 0101), Pilar, Buenos Aires
Hospital Italiano de Buenos Aires ( Site 0102), ABB, Caba
C.I.C.E. 9 de Julio ( Site 0104), San Miguel de Tucumán, Tucuman
Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0105), Santa Fe, Not set
Westmead Hospital ( Site 0201), Westmead, New South Wales
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0203), Adelaide, South Australia
Monash Health-Haematology Research ( Site 0202), Clayton, Victoria
Austin Health-Cancer Clinical Trials Centre ( Site 0206), Heidelberg, Victoria
Royal Perth Hospital-Haematology ( Site 0204), Perth, Western Australia
Ordensklinikum Linz GmbH Elisabethinen ( Site 0562), Linz, Oberosterreich
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0037), Greenfield Park, Quebec
Biocenter ( Site 0149), Concepcion, Biobio
IC La Serena Research ( Site 0150), La Serena., Coquimbo
FALP-UIDO ( Site 0148), Santiago, Region M. De Santiago
Clínica Inmunocel ( Site 0147), Santiago, Region M. De Santiago
Clínica Alemana de Santiago ( Site 0143), Santiago, Region M. De Santiago
Bradfordhill-Clinical Area ( Site 0142), Santiago, Region M. De Santiago
Fundacion Colombiana de Cancerología Clinica Vida ( Site 0164), Medellín, Antioquia
IMAT S.A.S ( Site 0162), Monteria, Cordoba
Los Cobos Medical Center ( Site 0165), Bogota, Distrito Capital De Bogota
Rigshospitalet-Hematology - CTU ( Site 0321), Copenhagen, Hovedstaden
Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 0324), Aarhus, Midtjylland
Roskilde Sygehus-Department of Hematology ( Site 0323), Roskilde, Sjaelland
Odense Universitetshospital-Department of Hematology ( Site 0325), Odense C, Syddanmark
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Hematology ( Site 0349), Nice, Alpes-Maritimes
CHU Bordeaux Haut-Leveque-service de mèdecine interne et maladies infectieuses ( Site 0346), Pessac, Aquitaine
Hôpital de la Conception ( Site 0351), Marseille, Bouches-du-Rhone
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 0352), Toulouse, Haute-Garonne
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 0344), Limoges, Haute-Vienne
Centre Hospitalier Régional Universitaire de Tours - Hôpital-Hématologie et Thérapie Cellulaire ( Site 0342), Tours, Indre-et-Loire
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu ( Site 0347), Nantes, Loire-Atlantique
centre hospitalier lyon sud ( Site 0343), Pierre-Bénite, Rhone
HENRI MONDOR HOSPITAL ( Site 0348), Creteil, Val-de-Marne
Hopital Saint-Louis ( Site 0341), Paris, Not set
VK&K Studien GbR ( Site 0370), Landshut, Bayern
Medizinische Hochschule Hannover ( Site 0371), Hannover, Niedersachsen
Universitätsklinikum Aachen ( Site 0367), Aachen, Nordrhein-Westfalen
Universitaetsklinikum Essen ( Site 0366), Essen, Nordrhein-Westfalen
Universitätsmedizin Johannes Gutenberg Universität Mainz-3. Medizinische Klinik und Poliklinik ( Site 0365), Mainz, Rheinland-Pfalz
Universitätsklinikum Halle ( Site 0361), Halle, Sachsen-Anhalt
Universitätsklinikum Jena-Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkolog ( Site 0364), Jena, Thuringen
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0369), Berlin, Not set
Queen Mary Hospital ( Site 0221), Hksar, Not set
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 0407), Szeged, Csongrad
Petz Aladar Egyetemi Oktato Korhaz-Hematológia ( Site 0405), Gyor, Gyor-Moson-Sopron
Somogy Vármegyei Kaposi Mór Oktató Kórház-Haematológiai osztály ( Site 0406), Kaposvár, Somogy
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 0404), Nyiregyhaza, Szabolcs-Szatmar-Bereg
Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0402), Debrecen, Not set
Soroka Medical Center ( Site 0427), Be'er Sheva, Not set
Rambam Health Care Campus ( Site 0429), Haifa, Not set
Carmel Hospital ( Site 0426), Haifa, Not set
Hadassah Medical Center ( Site 0424), Jerusalem, Not set
Galilee Medical Center ( Site 0431), Nahariya, Not set
Rabin Medical Center ( Site 0425), Petah Tikva, Not set
Sheba Medical Center ( Site 0428), Ramat Gan, Not set
Sourasky Medical Center ( Site 0422), Tel Aviv, Not set
Yitzhak Shamir Medical Center. ( Site 0421), Zerifin, Not set
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 0443), Alessandria, Ancona
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0447), Milano, Lombardia
Azienda Ospedaliera Universitaria Careggi ( Site 0441), Firenze, Toscana
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0446), Bologna, Not set
Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0444), Pavia, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0445), Roma, Not set
Ospedale di Circolo e Fondazione Macchi Varese ( Site 0442), Varese, Not set
Fujita Health University Hospital ( Site 0613), Toyoake, Aichi
Ehime University Hospital ( Site 0612), Toon, Ehime
Hokkaido University Hospital ( Site 0601), Sapporo, Hokkaido
Kobe City Medical Center General Hospital ( Site 0603), Kobe, Hyogo
Kanazawa University Hospital ( Site 0614), Kanazawa, Ishikawa
Mie University Hospital ( Site 0615), Tsu, Mie
National Hospital Organization Sendai Medical Center ( Site 0617), Sendai, Miyagi
Kansai Medical University Hospital ( Site 0607), Hirakata, Osaka
Kindai University Hospital ( Site 0600), Osakasayama, Osaka
Juntendo University Hospital ( Site 0611), Bunkyo-ku, Tokyo
University of Yamanashi Hospital ( Site 0606), Chuo, Yamanashi
Kyushu University Hospital ( Site 0605), Fukuoka, Not set
Fukushima Medical University Hospital ( Site 0616), Fukushima, Not set
University of Miyazaki Hospital ( Site 0609), Miyazaki, Not set
Okayama University Hospital ( Site 0604), Okayama, Not set
Nippon Medical School Hospital ( Site 0608), Tokyo, Not set
Medivest Centro de Investigación Integral ( Site 0183), Chihuahua City, Chihuahua
Higiea Oncologia ( Site 0184), Mexico City, Distrito Federal
Centro de Investigacion Clinica de Oaxaca ( Site 0181), Oaxaca de Juarez., Oaxaca
Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie-Oddział Hematoonkologii, Transplantacji Szp ( Site 0463), Lublin, Lubelskie
Pratia Onkologia Katowice ( Site 0461), Katowice, Slaskie
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 0466), Kielce, Swietokrzyskie
Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0490), Badalona, Barcelona
Hospital Universitario Marqués de Valdecilla-Haematology ( Site 0486), Santander, Cantabria
HOSPITAL CLÍNIC DE BARCELONA ( Site 0481), Barcelona, Cataluna
Institut Català d'Oncologia - L'Hospitalet ( Site 0482), L'Hospitalet de Llobregat, Cataluna
Clinica Universidad de Navarra-Hematology Department ( Site 0485), Madrid, Madrid, Comunidad De
Hospital Universitario Ramón y Cajal-Hematology ( Site 0484), Madrid, Madrid, Comunidad De
Hospital Costa del Sol-Hematology Service ( Site 0493), Marbella, Malaga
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0489), Barcelona, Not set
Hospital Universitario 12 de Octubre ( Site 0494), Madrid, Not set
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( Site 0488), Salamanca, Not set
Universitetssjukhuset Örebro ( Site 0542), Örebro, Orebro Lan
Skånes Universitetssjukhus Lund-Department of Hematology ( Site 0544), Lund, Skane Lan
Karolinska Universitetssjukhuset Huddinge ( Site 0541), Huddinge, Stockholms Lan
Akademiska sjukhuset ( Site 0545), Uppsala, Uppsala Lan
Sahlgrenska Universitetssjukhuset-Department of hematology and coagulation ( Site 0543), Gothenburg, Vastra Gotalands Lan
Chang Gung Memorial Hospital- Chiayi ( Site 0242), Chiayi City, Chiayi
National Cheng Kung University Hospital-Clinical Trial Center ( Site 0245), Tainan, Not set
National Taiwan University Hospital ( Site 0241), Taipei, Not set
Chang Gung Medical Foundation-Linkou Branch ( Site 0243), Taoyuan, Not set
Hacettepe Universite Hastaneleri-Department of Hematology ( Site 0505), Ankara, Not set
Medipol Mega Universite Hastanesi ( Site 0504), İstanbul, Not set
Glan Clwyd Hospital ( Site 0528), Bodelwyddan, Denbighshire
Gloucestershire Royal Hospital ( Site 0521), Gloucester, Gloucestershire
Lincoln County Hospital ( Site 0535), Lincoln, Great Britain
Boston Pilgrim Hospital ( Site 0525), Boston, Lincolnshire
University College London Hospital ( Site 0527), London, London, City Of
Guy's & St Thomas' NHS Foundation Trust ( Site 0523), London, London, City Of
Hammersmith Hospital ( Site 0533), London, London, City Of
Royal Gwent Hospital ( Site 0524), Newport, Not set
Conditions: Essential Thrombocythemia
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Recruiting
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).
Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin.
Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show:
* if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "p... Read More
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).
Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin.
Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show:
* if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo)
* Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study
* Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study.
This study is seeking for participants who:
* have non-segmental vitiligo (either active or stable) and
* received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it.
All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home.
Participants may receive the study medicine or placebo for up to 52 weeks.
The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo.
Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study.
Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending. Read Less
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/14/2025
Locations: California Dermatology & Clinical Research Institute, Encinitas, California +73 locations
California Dermatology & Clinical Research Institute, Encinitas, California
Marvel Clinical Research, Huntington Beach, California
Wallace Medical Group, Inc, Los Angeles, California
Encore Medical Research of Boynton Beach, Boynton Beach, Florida
Skin Care Research, Hollywood, Florida
ForCare Clinical Research, Tampa, Florida
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana
DelRicht Research, Baton Rouge, Louisiana
Lawrence J. Green, MD LLC, Rockville, Maryland
University of Michigan, Ann Arbor, Michigan
University of New Mexico Health Sciences Center, Albuquerque, New Mexico
SUNY Downstate Health Sciences University, Brooklyn, New York
University of North Carolina Medical Center, Chapel Hill, North Carolina
Clinical & Translational Research Center (CTRC), Chapel Hill, North Carolina
Accellacare - Wilmington, Wilmington, North Carolina
Wilmington Health, PLLC, Wilmington, North Carolina
University Hospitals Cleveland Medical Center, Cleveland, Ohio
Remington-Davis, Inc, Columbus, Ohio
Medical University of South Carolina, Charleston, South Carolina
Modern Research Associates, PLLC, Dallas, Texas
Alpesh D. Desai, DO PLLC, Houston, Texas
Austin Institute for Clinical Research, Houston, Texas
The Skin Hospital, Darlinghurst, New South Wales
North Eastern Health Specialists, Campbelltown, South Australia
Skin Health Institute Inc., Carlton, Victoria
Dr Rodney Sinclair Pty Ltd, East Melbourne, Victoria
The Alfred Hospital, Melbourne, Victoria
Medical Centre "Asklepiy", Dupnitsa, Kyustendil
Diagnostic Consultative Center Aleksandrovska, Sofia, Sofia (stolitsa)
UMHAT "Prof. Dr. Stoyan Kirkovich"AD, Stara Zagora, Not set
Dermatology Research Institute, Calgary, Alberta
CaRe Clinic, Red Deer, Alberta
Lynderm Research Inc., Markham, Ontario
DermEdge Research, Mississauga, Ontario
North York Research Inc, Toronto, Ontario
Centre de Recherche Dermatologique du Quebec metropolitain, Quebec, Not set
Centre de Recherche Saint-Louis inc., Quebec, Not set
Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong
Guangzhou First People's Hospital, Guangzhou, Guangdong
The First Hospital of Wuhan, Wuhan, Hubei
The First Hospital of China Medical University/Dermatology and STD Department, Shenyang, Liaoning
Huashan Hospital Fudan University, Shanghai, Shanghai
First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan
Praxis Leitz und Kollegen, Stuttgart, Baden-württemberg
Fachklinik Bad Bentheim, Bad Bentheim, Niedersachsen
Universitätsklinikum Münster, Münster, Nordrhein-westfalen
Nagoya City University Hospital, Nagoya, Aichi
Tohoku University Hospital, Sendai, Miyagi
Dermatology and Ophthalmology Kume Clinic, Sakai, Osaka
Nippon Medical School Hospital, Bunkyo-ku, Tokyo
Tokyo Medical University Hospital, Shinjuku-ku, Tokyo
Yamanashi Prefectural Central Hospital, Kofu, Yamanashi
The Catholic University Of Korea St. Vincent's Hospital, Suwon-si, Kyǒnggi-do
Ajou University Hospital, Suwon, Kyǒnggi-do
Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [seoul]
Hospital Infantil de Mexico Federico Gomez, Mexico City, Distrito Federal
Centro de Dermatologia de Monterrey, Monterrey, Nuevo LEÓN
Arké SMO S.A de C.V, Veracruz, Not set
Sociedad de Metabolismo y Corazon S.C., Veracruz, Not set
DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c., Osielsko, Kujawsko-pomorskie
Royalderm Agnieszka Nawrocka, Warszawa, Mazowieckie
Twoja Przychodnia SCM, Szczecin, Zachodniopomorskie
Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak, Lodz, Łódzkie
Dermedic Jacek Zdybski, Ostrowiec Swietokrzyski, Świętokrzyskie
Hospital Universitario Reina Sofia, Cordoba, Andalucía
Hospital Clínic de Barcelona, Barcelona, Catalunya [cataluña]
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, LAS Palmas
Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad DE
AUDIKA, Córdoba, Not set
Istanbul Universitesi Cerrahpasa, Istanbul- Fatih, Istanbul
Marmara Universitesi Pendik Egitim Arastirma Hastanesi, Istanbul, İ̇stanbul
Erciyes Universitesi Tıp Fakultesi Hastaneleri, Kayseri, Not set
Celal Bayar University Hafsa Sultan Hospital, Manisa, Not set
Guy's & St Thomas' NHS Foundation Trust, London, Not set
Conditions: Vitiligo
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Recruiting
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL).
This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people.
This study wi... Read More
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL).
This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people.
This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte, California +43 locations
City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte, California
IP Address: City of Hope Investigational Drug Services(IDS), Duarte, California
UCSD Medical Center - Encinitas, Encinitas, California
UC San Diego / Moores Cancer Center, La Jolla, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion), La Jolla, California
UC San Diego/Moores Cancer Center, La Jolla, California
UC San Diego Medical Center - Hillcrest, San Diego, California
UCSD Medical Center - Rancho Bernardo, San Diego, California
University of California San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California
UCSD Medical Center - Vista, Vista, California
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables, Florida
University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach, Florida
Sylvester Comprehensive Cancer Center - Hollywood, Hollywood, Florida
University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami, Florida
University Of Miami Hospitals And Clinics, Miami, Florida
Sylvester Comprehensive Cancer Center - Kendall, Miami, Florida
The University of Kansas Cancer Center, Investigational Drug Services, Fairway, Kansas
University of Kansas Clinical Research Center, Fairway, Kansas
The University of Kansas Hospital Cambridge Tower A, Kansas City, Kansas
The University of Kansas Hospital, Kansas City, Kansas
The University of Kansas Medical Center Medical Office Building, Kansas City, Kansas
The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas
The University of Kansas Cancer Center - Indian Creek Campus, Overland Park, Kansas
University of Kansas Cancer Center, Westwood, Kansas
The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri
Nebraska Medicine - Bellevue Medical Center, Bellevue, Nebraska
Nebraska Medical Center, Omaha, Nebraska
Nebraska Medicine - Village Pointe, Omaha, Nebraska
University of Nebraska Medical Center, Omaha, Nebraska
Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Roswell Park Comprehensive Cancer Center, Buffalo, New York
Fred Hutchinson Cancer Research Center | Seattle, WA, Seattle, Washington
University of Washington, Seattle, Washington
Rigshospitalet University Hospital of Copenhagen, Copenhagen Ø, Not set
Chu Saint Eloi, Montpellier, Languedoc-roussillon
Centre Hospitalier Universitaire (CHU) de Caen, Caen, Not set
Centre Hospitalier Lyon Sud, Pierre-Benite Cedex, Not set
Institut Gustave Roussy, Villejuif Cedex, Not set
Charite Universitatsmedizin Berlin, Berlin, Not set
Centro Ricerche Cliniche di Verona s.r.l., Verona, Not set
Hospital Universitari Vall d'Hebron, Barcelona, Not set
The Royal Marsden NHS Foundation Trust (RM), London, Not set
The Christie NHS Foundation Trust, Manchester, Not set
Conditions: Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Recruiting
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progr... Read More
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona +241 locations
Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona
Banner MD Anderson Cancer Center-Oncology ( Site 0004), Gilbert, Arizona
Providence Medical Foundation-Oncology ( Site 0020), Fullerton, California
Moores Cancer Center ( Site 0059), La Jolla, California
Cancer and Blood Specialty Clinic ( Site 0001), Los Alamitos, California
University of Colorado Anschutz Medical Campus ( Site 0061), Aurora, Colorado
UCHealth Cherry Creek Medical Center ( Site 0094), Denver, Colorado
University of Colorado Health - Highlands Ranch Hospital ( Site 0095), Highlands Ranch, Colorado
Yale Cancer Center ( Site 0060), New Haven, Connecticut
Stamford Hospital ( Site 0049), Stamford, Connecticut
AdventHealth Altamonte Springs ( Site 0021), Altamonte Springs, Florida
University of Florida College of Medicine ( Site 0063), Gainesville, Florida
Orlando Health Cancer Institute ( Site 0011), Orlando, Florida
Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville, Georgia
University of Chicago Medical Center ( Site 0067), Chicago, Illinois
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053), Edgewood, Kentucky
Mary Bird Perkins Cancer Center-Breast & GYN Pavilion ( Site 0042), Baton Rouge, Louisiana
Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore, Maryland
Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028), Baltimore, Maryland
Holy Cross Hospital ( Site 0073), Silver Spring, Maryland
Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037), Boston, Massachusetts
Henry Ford Health ( Site 0002), Detroit, Michigan
Saint Luke's Cancer Institute ( Site 0027), Kansas City, Missouri
Washington University School of Medicine ( Site 0076), Saint Louis, Missouri
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0068), New York, New York
Hematology Oncology Associates of Rockland ( Site 0054), Nyack, New York
Stony Brook University-Cancer Center ( Site 0034), Stony Brook, New York
Levine Cancer Institute ( Site 0014), Charlotte, North Carolina
Zangmeister Cancer Center ( Site 7000), Columbus, Ohio
Providence Portland Medical Center ( Site 0044), Portland, Oregon
Providence St. Vincent Medical Center ( Site 0081), Portland, Oregon
Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia, Pennsylvania
Texas Oncology-Dallas Presbyterian Hospital ( Site 8000), Dallas, Texas
The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth, Texas
Texas Oncology - San Antonio ( Site 8002), San Antonio, Texas
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0057), Tyler, Texas
Inova Schar Cancer Institute ( Site 0025), Fairfax, Virginia
Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian, Virginia
VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond, Virginia
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8001), Roanoke, Virginia
University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison, Wisconsin
Instituto Alexander Fleming-Alexander Fleming ( Site 0382), Ciudad Autónoma de Buenos Aires, Caba
Fundacion Estudios Clinicos-Oncology ( Site 0384), Rosario, Santa Fe
Hospital Aleman-Oncology ( Site 0386), Buenos Aires, Not set
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0383), Buenos Aires, Not set
Hospital Italiano de Córdoba ( Site 0385), Cordoba, Not set
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0387), La Rioja, Not set
Macquarie University-MQ Health Clinical Trials Unit ( Site 2002), Macquarie University, New South Wales
Westmead Hospital ( Site 2000), Westmead, New South Wales
Frankston Hospital-Oncology and Haematology ( Site 2003), Frankston, Victoria
Fiona Stanley Hospital-Medical Oncology ( Site 2004), Murdoch, Western Australia
Institut Jules Bordet-Medicine Oncology ( Site 1104), Anderlecht, Bruxelles-Capitale, Region De
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1103), Brussels, Bruxelles-Capitale, Region De
Jessa Ziekenhuis-Limburgs Oncologisch Centrum ( Site 1105), Hasselt, Limburg
AZ Maria Middelares-IKG ( Site 1106), Gent, Oost-Vlaanderen
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 1107), Namur, Not set
Oncoclínica Oncologistas Associados-Clinical Research ( Site 0407), Teresina, Piaui
Hospital Moinhos de Vento ( Site 0403), Porto Alegre, Rio Grande Do Sul
Hospital do Câncer Mãe de Deus ( Site 0404), Porto Alegre, Rio Grande Do Sul
Instituto de Oncologia Saint Gallen ( Site 0412), Santa Cruz do Sul, Rio Grande Do Sul
Instituto do Câncer Brasil - Unidade Taubaté ( Site 0408), Taubaté, Sao Paulo
IBCC - Núcleo de Pesquisa e Ensino ( Site 0401), Sao Paulo, Not set
BC Cancer Surrey ( Site 0315), Surrey, British Columbia
Southlake Regional Health Centre ( Site 0311), Newmarket, Ontario
Princess Margaret Cancer Centre ( Site 0310), Toronto, Ontario
CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0301), Montreal, Quebec
Jewish General Hospital ( Site 0303), Montreal, Quebec
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski ( Site 0308), Rimouski, Quebec
CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0302), Quebec, Not set
Oncovida ( Site 0453), Santiago., Region M. De Santiago
Clínica RedSalud Vitacura ( Site 0455), Santiago., Region M. De Santiago
FALP-UIDO ( Site 0451), Santiago, Region M. De Santiago
Pontificia Universidad Catolica de Chile ( Site 0454), Santiago, Region M. De Santiago
Bradfordhill ( Site 0452), Santiago, Region M. De Santiago
Bradford Hill Norte ( Site 0456), Antofagasta, Not set
Fundacion Colombiana de Cancerología Clinica Vida ( Site 0506), Medellín, Antioquia
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0501), Valledupar, Cesar
IMAT S.A.S ( Site 0502), Monteria., Cordoba
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0507), Bogota, Distrito Capital De Bogota
Fundación Valle del Lili ( Site 0508), Cali, Valle Del Cauca
CIMCA ( Site 0551), San José, San Jose
Hospital Metropolitano - Sede Lindora ( Site 0550), Santa Ana, San Jose
ICIMED ( Site 0552), San Jose, Not set
Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 1138), Ceske Budejovice, Jihocesky Kraj
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 1134), Ostrava-Poruba, Moravskoslezsky Kraj
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1132), Olomouc, Olomoucky Kraj
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 1136), Praha, Praha 5
Fakultni nemocnice Kralovske Vinohrady-Onkologická klinika ( Site 1135), Praha 10, Not set
Rigshospitalet ( Site 1180), Copenhagen, Hovedstaden
Nordsjællands Hospital - Hillerød ( Site 1184), Hillerod, Hovedstaden
Næstved Sygehus ( Site 1182), Naestved, Sjaelland
Odense Universitetshospital ( Site 1181), Odense C, Syddanmark
Vejle Sygehus ( Site 1183), Vejle, Syddanmark
Centre François Baclesse ( Site 1250), Caen, Calvados
Centre de Cancérologie du Grand Montpellier ( Site 1244), Montpellier, Languedoc-Roussillon
Hôpital privé du Confluent SAS-Service d'oncologie médicale ( Site 1242), Nantes, Loire-Atlantique
Pitie Salpetriere University Hospital ( Site 1249), Paris, Orne
Hopital Prive Jean Mermoz-Oncology ( Site 1246), Lyon, Rhone-Alpes
Centre Hospitalier Universitaire de Poitiers-Pôle régional de cancérologie ( Site 1243), Poitiers, Vienne
Institut Curie-Oncology medical Department ( Site 1240), Paris, Not set
SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1315), Gera, Thuringen
Helios Klinikum Berlin-Buch-Klinik für Gynäkologie und Geburtshilfe ( Site 1314), Berlin, Not set
Errikos Dunant Hospital Center ( Site 1348), Athens, Attiki
Aretaieio Hospital Oncology Unit ( Site 1345), Athens, Attiki
Hygeia Hospital ( Site 1346), Marousi, Attiki
University General Hospital of Larissa ( Site 1343), Larissa, Thessalia
Agios Loukas Clinic ( Site 1347), Thessaloniki, Not set
European Interbalkan Medical Center ( Site 1341), Thessaloniki, Not set
Queen Mary Hospital ( Site 2040), Hksar, Not set
Prince of Wales Hospital ( Site 2041), Shatin, Not set
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterápiás Klinika ( Site 1379), Szeged, Csongrad
Somogy Vármegyei Kaposi Mór Oktató Kórház-Oncology center ( Site 1371), Kaposvár, Somogy
Zala Vármegyei Szent Rafael Kórház-Onkológiai osztály ( Site 1372), Zalaegerszeg, Zala
Semmelweis Egyetem-Belgyógyászati és Onkológiai Klinika ( Site 1381), Budapest, Not set
Budapesti Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 1373), Budapest, Not set
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 1375), Debrecen, Not set
All India Institute of Medical Sciences ( Site 2051), New Delhi, Delhi
Rajiv Gandhi Cancer Institute And Research Centre-Department of Clinical Research ( Site 2052), New Delhi, Delhi
Tata Memorial Hospital-Medical Oncology ( Site 2053), Mumbai, Maharashtra
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute-Centre for cancer ( Site 2056), Mumbai, Maharashtra
Bon Secours Cork Hospital ( Site 1422), Cork, Not set
St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1420), Dublin, Not set
Mater Misericordiae University Hospital-Clinical Trials Research Unit ( Site 1423), Dublin, Not set
Rambam Health Care Campus-Oncology Division ( Site 1452), Haifa, Not set
Hadassah Medical Center ( Site 1451), Jerusalem, Not set
Rabin Medical Center ( Site 1453), Petah Tikva, Not set
Sheba Medical Center ( Site 1450), Ramat Gan, Not set
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1480), Meldola, Forli-Cesena
CRO-IRCCS ( Site 1478), Aviano, Friuli-Venezia Giulia
Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1475), Milano, Lombardia
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1472), Milan, Lombardia
Istituto Clinico Humanitas ( Site 1476), Rozzano, Milano
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1474), Bologna, Not set
Ospedale San Martino ( Site 1479), Genova, Not set
Ospedale San Raffaele-Oncologia Medica ( Site 1471), Milano, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1477), Roma, Not set
Nagoya City University Hospital ( Site 2474), Nagoya, Aichi
Hokkaido University Hospital ( Site 2460), Sapporo, Hokkaido
Tokai University Hospital ( Site 2473), Isehara, Kanagawa
St. Marianna University Hospital ( Site 2465), Kawasaki, Kanagawa
Kitasato University Hospital ( Site 2471), Sagamihara, Kanagawa
Kanagawa Cancer Center ( Site 2472), Yokohama, Kanagawa
Mie University Hospital ( Site 2483), Tsu, Mie
Tohoku University Hospital ( Site 2482), Sendai, Miyagi
The University of Osaka Hospital ( Site 2476), Suita, Osaka
Saitama Medical University International Medical Center ( Site 2462), Hidaka, Saitama
Juntendo University Hospital ( Site 2468), Bunkyo, Tokyo
Cancer Institute Hospital of JFCR ( Site 2464), Koto, Tokyo
Showa Medical University Hospital ( Site 2466), Shinagawa, Tokyo
Tokyo Medical University Hospital ( Site 2467), Shinjuku, Tokyo
National Center for Global Health and Medicine ( Site 2469), Shinjuku, Tokyo
Fukushima Medical University Hospital ( Site 2461), Fukushima, Not set
Gifu University Hospital ( Site 2486), Gifu, Not set
Hiroshima City Hiroshima Citizens Hospital ( Site 2478), Hiroshima, Not set
Social medical corporation Hakuaikai Sagara Hospital ( Site 2481), Kagoshima, Not set
Kumamoto University Hospital ( Site 2480), Kumamoto, Not set
Kyoto University Hospital ( Site 2475), Kyoto, Not set
Okayama University Hospital ( Site 2485), Okayama, Not set
Osaka International Cancer Institute ( Site 2477), Osaka, Not set
Seoul National University Hospital-Internal Medicine ( Site 2353), Seoul, Not set
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 2350), Seoul, Not set
Asan Medical Center-Department of Oncology ( Site 2352), Seoul, Not set
Samsung Medical Center-Division of Hematology/Oncology ( Site 2351), Seoul, Not set
Hospital Sultan Ismail ( Site 2153), Johor Bahru, Johor
Sarawak General Hospital ( Site 2154), Kuching, Sarawak
Pantai Hospital Kuala Lumpur ( Site 2151), Kuala Lumpur, Not set
Health Pharma Professional Research S.A. de C.V: ( Site 0598), Ciudad de México, Distrito Federal
Grupo Médico ASSET-Clinical Research ( Site 0596), Mexico City, Distrito Federal
CIO - Centro de Inmuno-Oncología de Occidente ( Site 0592), Guadalajara, Jalisco
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 0590), Monterrey, Nuevo Leon
CENTRO MEDICO ZAMBRANO HELLION-Centro de Cáncer de Mama ( Site 0595), San Pedro Garza Garcia, Nuevo Leon
Ziekenhuis Rijnstate-Rijnstate Centrum Oncologisch Onderzoek ( Site 1524), Arnhem, Gelderland
Maastricht UMC+-Medical Oncology ( Site 1522), Maastricht, Limburg
Amphia Ziekenhuis, locatie Breda Molengracht-oncologie ( Site 1523), Breda, Noord-Brabant
Catharina Ziekenhuis ( Site 1526), Eindhoven, Noord-Brabant
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1520), Amsterdam, Noord-Holland
Isala, locatie Zwolle ( Site 1525), Zwolle, Overijssel
Meander Medisch Centrum ( Site 1521), Amersfoort, Utrecht
Auckland City Hospital ( Site 2031), Auckland, Not set
Clinica Vallesur - AUNA ( Site 0652), Arequipa, Ariqipa
Hospital Militar Central Luis Arias Schereiber ( Site 0651), Jesús María, Lima
Oncosalud ( Site 0650), Lima, Muni Metro De Lima
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0653), Lima, Not set
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1582), Bydgoszcz, Kujawsko-pomorskie
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1584), Siedlce, Mazowieckie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii ( Site 1580), Warszawa, Mazowieckie
Mazowiecki Szpital Onkologiczny ( Site 1581), Wieliszew, Mazowieckie
Mrukmed-Mrukmed ( Site 1592), Rzeszow, Podkarpackie
Bialostockie Centrum Onkologii ( Site 1585), Bialystok, Podlaskie
Szpitale Pomorskie Sp. z o. o.-Oddział Onkologii Klinicznej ( Site 1593), Gdynia, Pomorskie
Narodowy Instytut Onkologii - Oddzial w Gliwicach-Centrum Diagnostyki i Leczenia Chorob Piersi ( Site 1590), Gliwice, Slaskie
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1595), Kielce, Swietokrzyskie
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1583), Koszalin, Zachodniopomorskie
Zachodniopomorskie Centrum Onkologii ( Site 1588), Szczecin, Zachodniopomorskie
Unidade Local de Saude Amadora/Sintra - Hospital Prof Dr Fernando Fonseca ( Site 1663), Lisbon, Lisboa
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1661), Lisboa, Not set
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1662), Porto, Not set
Puerto Rico Medical Research Center LLC ( Site 0675), Hato Rey, Not set
UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0677), San Juan, Not set
Spitalul Clinic Filantropia ( Site 1703), București, Bucuresti
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 1702), Florești, Cluj
Centrul Medical Neolife- Baneasa ( Site 1704), Bucuresti, Not set
Institutul Oncologic Cluj ( Site 1701), Cluj, Not set
National University Hospital ( Site 2250), Singapore, Central Singapore
Mount Alvernia ICON Cancer Center ( Site 2251), Singapore, North East
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2905), Port Elizabeth, Eastern Cape
Curo Oncology ( Site 2908), Pretoria, Gauteng
Sandton Oncology Medical Group (Pty) Ltd ( Site 2911), Sandton, Gauteng
Cancercare Rondebosch Oncology-Clinical trials ( Site 2904), Rondebosch, Western Cape
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1758), Pozuelo de Alarcon, Madrid
HOSPITAL CLINICO DE VALENCIA-Oncology ( Site 1752), Valencia, Valenciana, Comunitat
Hospital Universitari Vall d'Hebron-Oncology ( Site 1750), Barcelona, Not set
Hospital Universitario Reina Sofia-Oncologia Medica ( Site 1754), Cordoba, Not set
Hospital Beata María Ana-oncology ( Site 1755), Madrid, Not set
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 1756), Madrid, Not set
Hospital Universitario Virgen Macarena ( Site 1757), Sevilla, Not set
Karolinska Universitetssjukhuset Solna ( Site 1801), Stockholm, Stockholms Lan
Akademiska sjukhuset ( Site 1802), Uppsala, Uppsala Lan
Södra Älvsborgs Sjukhus Borås ( Site 1803), Borås, Vastra Gotalands Lan
University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 1844), Basel, Basel-Stadt
Spital Thun ( Site 1840), Thun, Berne
Brust-Zentrum ( Site 1841), Zürich, Zurich
Changhua Christian Hospital ( Site 2410), Changhua, Not set
Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 2413), Kaohsiung, Not set
National Cheng Kung University Hospital-Surgery ( Site 2411), Tainan, Not set
National Taiwan University Hospital-Oncology ( Site 2415), Taipei, Not set
Mackay Memorial Hospital ( Site 2412), Taipei, Not set
Chang Gung Medical Foundation-Linkou Branch-General Surgery ( Site 2414), Taoyuan, Not set
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1878), Yenimahalle, Ankara
Medipol Mega Universite Hastanesi-oncology ( Site 1875), Stanbul, Istanbul
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1876), Adana, Not set
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1870), Ankara, Not set
Memorial Ankara Hastanesi-Medical Oncology ( Site 1874), Ankara, Not set
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1871), Ankara, Not set
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1872), Istanbul, Not set
Samsun Medical Park Hastanesi-medical oncology ( Site 1873), Samsun, Not set
North West Cancer Centre ( Site 1944), Londonderry, Derry And Strabane
The Royal Cornwall Hospital ( Site 1943), Truro, England
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1940), London, London, City Of
University College London Hospital-Cancer Clinical Trials Unit ( Site 1942), London, London, City Of
Blackpool Victoria Hospital ( Site 1941), Blackpool, Not set
City Hospital, Nottingham University Hospitals NHS Trust ( Site 1945), Nottingham, Not set
Conditions: Breast Neoplasms
217 - 228 of 3097